Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HRS 2011: What's Hot, What's Not, in AF Ablation

Executive Summary

Presenters at a day-long AF Symposium held just prior to this year's Heart Rhythm Society meeting lamented the disappointing long-term results with AF ablation and spoke about upcoming technological advances in catheters and adjunctive tools that may improve the procedure's efficacy and durability.

You may also be interested in...



New Paradigms Brewing In Atrial Fibrillation Ablation

Groundbreaking new mapping technologies could shift the future direction of the $2.5 billion AF ablation market, as evidenced by presentations at this year’s HRS and EUROPACE meetings; with some compelling clinical data now on the books, the electrophysiologists who perform AF ablation are taking notice, as are investors and strategics operating in this space. Emerging companies at the heart of this shift include Topera Medical, CardioInsight Technologies, and Acutus Medical.

The Medical Device Industry Stays The Course In 2012

The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, provided the industry with some momentum.

Device Companies Follow New Map To Atrial Fibrillation

Device therapies for atrial fibrillation (AF) have so far failed to result in compelling efficacy across all types of disease and patients. The rates of elimination of AF following a catheter ablation procedure range from 30% to 80% according to the type of patient and the definition of success. The question of why success rates aren’t yet sufficient after a great deal of investment is an area of active pursuit, and one that opens up the door for next-generation AF device companies seeking to improve upon the results achieved to date.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel